Tag: T-cell Activation
-
How Etentamig Redirects T Cells in Multiple Myeloma
Etentamig is a BCMA × CD3 bispecific T-cell engager designed with bivalent BCMA binding, low-affinity CD3 engagement and retained FcRn binding to redirect T cells against multiple myeloma cells.
-
How Moderna’s Personalized mRNA Cancer Therapy Trains the Immune System
This BP Science explainer shows how intismeran uses patient-specific tumor mutations to create a personalized mRNA neoantigen therapy, activate tumor-specific T cells, and work together with Keytruda to sustain anti-tumor immunity.